NDAINHALATIONPOWDER
Approved
Mar 2013
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Mechanism of Action
Pharmacologic Class:
Aminoglycoside Antibacterial
Clinical Trials (5)
Tobramycin Injection to Prevent Infection in Open Fractures
Started Jan 2022
600 enrolled
Wound InfectionFractures, OpenSurgical Site Infection
Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation
Started Oct 2018
Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
Started Feb 2017
107 enrolled
Non-cystic Fibrosis Bronchiectasis
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
Started Jan 2014
32 enrolled
Cystic Fibrosis
Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)
Started Aug 2013
60 enrolled
Cystic Fibrosis
Loss of Exclusivity
LOE Date
Nov 4, 2030
56 months away
Patent Expiry
Nov 4, 2030